TF and cancer: A recent trial showed an increased risk of VTE (HR 2.0) with elevated TF+EV-dependent procoagulant activity (based on FVII dependence in a fibrin generation test) prospectively measured in 648 cancer patients (40 of whom developed VTE within 6 months), and this risk was most pronounced in pancreatic cancer patients (HR 4.1) [59].